[ad_1]
The COVID-19 vaccine is expected to arrive in Latin America in March or April 2021, after being distributed to the United States and Europe, according to the pharmaceutical group that will produce the Oxford vaccine.
So far, none of the 175 vaccines that are being developed in the world have been approved for commercialization.
However, the approval of some of the vaccines should occur soon, at the end of this month or next, if unforeseen events do not arise, recalled Hugo Sigman, founder and CEO of the pharmaceutical group Insud, which will produce the vaccine developed by the University of Oxford and AstraZeneca.
The statements of the pharmacist Hugo Sigman were made today during the online seminar organized by the Organization of Ibero-American States (OEI) and are being quoted by the Spanish news agency EFE.
According to the pharmacist, it is not yet possible to know how long the antibodies of a vaccinated person will last, but it is expected to be at least a year, as is the case with the flu vaccine.
The Oxford University vaccine, along with the candidate from Pfizer and BioNTechque, are currently identified as being the most likely to be the first to be submitted for regulatory approval.
“All Ibero-American countries are making very important purchase plans,” said the pharmacist.
In Portugal, the Government authorized the purchase of 6.9 million vaccines against covid-19, which will cost 20 million euros, through a process that is being coordinated between countries of the European Union (EU).
Regarding the criticisms of those who fear that the harm of taking a vaccine is greater than the benefits, the pharmacist guaranteed that the safety mechanisms are “very good” and that “the cost-benefit of being vaccinated is greater than that of not being vaccinated “.
The goal is for at least 70% of the population to be vaccinated to create group immunity.
The pharmacist recalled that the covid-19 arrived to strengthen the process of preparing a type of vaccine that had already begun with the prevention of other coronaviruses.
Laboratories were already working to combat SARS (Severe Acute Respiratory Syndrome, which in Portuguese translates as Severe Acute Respiratory Syndrome), which was first identified in 2003, as well as MERS (Middle East Respiratory Syndrome), which emerged in 2012.
Hugo Sigman also expressed confidence in how the pandemic will evolve in the next year, since the measures for the treatment and prevention of the disease will already be known and because there will be a greater notification of asymptomatic cases, which can reduce the spread. of the virus.
The covid-19 pandemic has already claimed more than 1.2 million deaths in more than 47.5 million cases of infection worldwide, according to a report by the French agency AFP.
In Portugal 2,694 people died out of 156,940 confirmed cases of infection, according to the most recent bulletin from the Directorate General of Health.
The disease is transmitted by a new coronavirus detected at the end of December 2019 in Wuhan, a city in central China.
[ad_2]
